> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# J&J Reports Positive Data in Psoriasis Drug
- URL: https://www.fdaweb.com/j-j-reports-positive-data-in-psoriasis-drug/
- Published: 2025-09-17T12:00:00.000Z
- Updated: 2026-09-14T15:21:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159881

Johnson & Johnson says data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies showed that its experimental psoriasis drug icotrokinra outperformed Bristol Myers Squibb’s oral therapy deucravacitinib in patients with moderate-to-severe plaque psoriasis.Pesented at the European Academy of Dermatology and Venereology (EADV) Congress, the data also demonstrated that icotrokinra achieved higher rates of complete skin clearance at weeks 16 and 24 while maintaining a safety profile similar to placebo, it says. Adverse events were numerically lower compared with deucravacitinib, and no new safety signals were identified.

In addition, J&J reported new 52-week results from its ICONIC-LEAD trial that evaluated icotrokinra in both adults and adolescents. Among adults who had already responded to treatment by week 24, 84% maintained their response at week 52 compared to 21% of those who switched to placebo, it says. In adolescents, 86% of patients who received icotrokinra continuously for a year achieved strong clearance rates, along with 77% of those who switched from placebo at week 16.